|
Market Closed -
Nasdaq
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 1.660 USD | -2.35% |
|
0.00% | -8.79% |
Company Valuation: Alzamend Neuro, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: April | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 7.954 | - |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 83.38% | - |
| Enterprise Value (EV) | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 7.954 | 7.954 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 83.38% | 0% |
| P/E | -7.29x | -3.65x | -0.48x | -0.52x | -0.43x | -1.58x | -1.91x |
| PBR | 7.3x | - | -1.85x | - | 6.62x | 41.5x | -2.63x |
| PEG | - | -0.51x | 0x | 0x | 0x | 0x | 0.1x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -0.97x | -0.97x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.74x | -0.74x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -189 | -202.5 | -132.3 | -11.32 | -2.63 | -1.05 | -0.87 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | -7.907 | -11.26 | -8.931 | -4.121 | -7.949 | -8.2 | -8.2 |
| EBIT 1 | -12.32 | -14.87 | -9.938 | -4.497 | -8.767 | -10.8 | -10.8 |
| Net income 1 | -12.36 | -14.88 | -9.948 | -5.105 | -8.772 | -10.8 | -10.8 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 1,377.000 | 738.855 | 63.990 | 5.940 | 1.140 | 1.660 | 1.660 |
| Nbr of stocks (in thousands) | 68.9 | 71.8 | 76.3 | 734 | 3,805 | 4,792 | - |
| Announcement Date | 7/19/22 | 7/27/23 | 7/30/24 | 7/22/25 | 7/22/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.58x | - | - | - | 7.95M | |
| 33.15x | 5.95x | 17.82x | 0.98% | 48.93B | |
| -21.5x | 245.64x | -23.19x | -.--% | 45.01B | |
| 34.48x | 3.33x | 14.35x | -.--% | 44.07B | |
| 46.93x | 5.41x | 29.72x | -.--% | 40.73B | |
| 28.42x | 8.6x | 21.8x | 0.4% | 33.52B | |
| 33.62x | 5.51x | 25.02x | -.--% | 16.5B | |
| 24.24x | 2.11x | 9.11x | 1.11% | 14.67B | |
| 77.18x | 4.06x | 15.75x | -.--% | 13.77B | |
| Average | 28.33x | 35.07x | 13.80x | 0.31% | 28.58B | |
| Weighted average by Cap. | 27.26x | 47.36x | 12.31x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALZN Stock
- Valuation Alzamend Neuro, Inc.
Select your edition
All financial news and data tailored to specific country editions
